CAR T-Cell Therapy Market by Target Antigens (CD19, BCMA, CD20, CD19/22, and Other Target Antigens), Target Indication (Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Large B-cell Lymphoma, Mantle Cell Lymphoma, Multiple

CAR T-Cell Therapy Market by Target Antigens (CD19, BCMA, CD20, CD19/22, and Other Target Antigens), Target Indication (Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Large B-cell Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma, and Others), Key Geographies (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World), Sales Forecast of Drugs and Leading Players: Industry Trends and Global Forecasts, Till 2035

CAR T-CELL THERAPY MARKET: OVERVIEW

As per Roots Analysis, the global CAR T-cell therapy market is estimated to grow from USD 4.6 billion in the current year to USD 15.2 billion by 2035, at a CAGR of 11.4% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Target Indication

Acute Lymphoblastic Leukemia

Diffuse Large B-cell Lymphoma

Follicular Lymphoma

Large B-cell Lymphoma

Mantle Cell Lymphoma

Multiple Myeloma

Others

Target Antigen

CD19

BCMA

CD20

CD19 / CD22

Others

Key Players

Gilead Sciences

Bristol Myers Squibb

Novartis

Janssen

JW Therapeutics

Key Geographical Regions

North America

US

Canada

Europe

Germany

France

Italy

Spain

UK

Rest of Europe

Asia-Pacific

Japan

India

China

Australia

South Korea

Rest of Asia Pacific

Latin America

Middle East and North Africa

Rest of the World

Key Drugs

Yescarta

Kymriah

Abecma

Breyanzi

Carvykti

Tecartus

Others

CAR T-CELL THERAPY MARKET: GROWTH AND TRENDS

Cancer research continues to be one of the most active segments, in terms of drug development, within the pharmaceutical industry. In fact, in the past few years, the USFDA has approved more than 70 drugs for the treatment of different types of cancer. Given the challenges associated with conventional therapies, such as non-specificity, drug developers are actively investigating more targeted anti-cancer therapies. Of these, CAR T-cell therapies have emerged as a promising option. CAR T-cell therapy leverages the body’s own immune system to target and eliminate cancer cells. CAR-T cell therapies have been demonstrated to enable complete disease remission, omitting the need for additional treatment; several studies have proven the efficacy of these therapy candidates. It is worth highlighting that close to 1,000 clinical trials related to CAR-T cell therapies have been registered in the past eight years, indicating substantial research activity. At present, over 230 companies are engaged in the development of CAR T-cell therapies for the treatment of different oncological, non-oncological and other disorders.

Along with the technological advancements in molecular research, the surge in demand for personalized cancer treatment and increase in the number of clinical trials and multiple therapy approvals are some other considerable factors, aiding the growth of this market. Furthermore, continuous financial support from investors is expected to propel the steady growth for the development of CAR-T cell therapy in the mid to long-term.

CAR T-CELL THERAPY MARKET: KEY INSIGHTS

The report delves into the current state of the CAR T-cell therapy market and identifies potential growth opportunities within the industry. Some key findings from the report include:

1. CAR-T cell therapies, with over 1240 preclinical / clinical product candidates, represent one of the most active segments in the pharmaceutical domain.

2. Close to 75% of the therapy candidates, which are being developed to target a range of disease indications, are autologous in nature; notably, CD19 and BCMA have emerged as the most popular target antigens.

3. Extensive efforts are underway to improve CAR constructs across successive generations, involving alterations in the scFv region via using different types of gene delivery vectors.

4. Close to 200 players claim to have the required capabilities to manufacture different types of cell therapies; such firms also offer a wide range of services across different stages of product development.

5. In the last eight years, over 970 clinical trials have been registered across different geographies for CAR-T cell therapies; extensive efforts are underway to improve successive generations of these therapies.

6. 375+ scientists from renowned universities are presently involved in the clinical development of CAR-T cell therapies; these KOLs are primarily based in the US and China.

7. The rise in partnerships, in the recent past, involving both international and indigenous stakeholders, validate the growing interest in this domain.

8. Several investors, having realized the opportunity within this upcoming segment of cancer immunotherapy, have invested more than USD 32 billion, across 370+ instances.

9. More than 11,900 patents related to CAR-T cell therapies have been filed / granted to protect the intellectual property generated within this field.

10. In order to efficiently promote these therapies and sustain their position in the CAR-T cell therapies market, drug developers are actively exploring diverse promotional strategies.

11. Considering the growing prevalence of cancer, technological developments and ongoing approvals, the market for CAR-T cell therapies is poised to witness a steady growth in the foreseen future.

12. With a growing focus on the development pipeline and encouraging clinical results, the market is anticipated to witness an annualized growth rate of over 10%, during the next decade.

CAR T-CELL THERAPY MARKET: KEY SEGMENTS

Multiple Myeloma is Likely to Dominate the CAR T-Cell Therapy Market During the Forecast Period

Based on target indication, the market is segmented into acute lymphoblastic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, large B-cell lymphoma, mantle cell lymphoma, multiple myeloma and others. It is worth highlighting that the market for CAR-T therapies designed to treat large B-cell lymphoma is projected to grow at an annual growth rate of 14%, during the forecast period.

CD19 Targeting Therapies is Expected to Capture Largest Share in the CAR T-Cell Therapy Market During the Forecast Period

Based on target antigen, the market is segmented into CD19, BCMA, CD20, CD19 / CD22 and others. It is worth highlighting that the segment for CD19 is likely to capture more than 65% of the overall market in the coming years. This can be attributed to the success of CD19 targeting therapies, such as Kymriah® (tisagenlecleucel) and Yescarta® (axicabtagene ciloleucel).

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World. It is worth highlighting that over the years, the market in Asia-Pacific is expected to grow at a higher CAGR.

Example Players in the CAR T-Cell Therapy Market

Autolus

Bluebird Bio

Bristol Myers Squibb

Carsgen Therapeutics

Cellectis, Gilead Sciences

Innovative Cellular Therapeutics

Noile-Immune Biotech

Novartis

Shanghai GeneChem

Sinobioway Cell Therapy

Takara Bio

Wellington Zhaotai Therapies

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

Chief Executive Officer, Glycostem Therapeutics

Chief Executive Officer, Gracell Biotechnologies

Chief Operating Officer, TxCell

Vice President, Scientific Affairs, Kite Pharma

Vice President, Immuno-Oncology, Celyad

Manager of Business Development, Waisman Biomanufacturing Competitive Intelligence Manager, Strategy & Business Development, Theravectys

Professor of Medicine and Director, Department of Oncology, Changhai Hospital

Assistant Professor of Medicine, University of Colorado

CAR T-CELL THERAPY MARKET: RESEARCH COVERAGE

The report features an in-depth analysis of the CAR T-cell therapy market, focusing on key market segments, including target antigens, target indication, key geographical regions, sales forecast of drugs and leading players.

The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting the market growth.

A comprehensive evaluation of the current market landscape of CAR-T cell therapies, considering various parameters, such as type of developer (industry and non-industry), phase of development (approved, phase III, phase II / III, phase II, phase I / II, phase I, clinical (phase unknown), preclinical), therapeutic area (oncological disorders, non-oncological disorders and undisclosed), key target indication (acute lymphoblastic leukemia, B-cell lymphoma, multiple myeloma, non-Hodgkin lymphoma, acute myeloid leukemia, hepatocellular carcinoma, diffuse large B-cell lymphoma, pancreatic cancer, gastric cancer, lung cancer, mantle cell lymphoma, ovarian cancer, HER2-positive breast cancer and follicular lymphoma), key target antigen (CD19, BCMA, CD19 / CD22, GPC3, NY-ESO-1 and others), source of T-cells (autologous and allogeneic), route of administration (intravenous, intratumoral, intraperitoneal, intrapleural, intracranial and others), dose frequency (single dose, multiple doses and split doses), patient segment (children, adults and seniors) and type of therapy (monotherapy and combination therapy). It also provides an assessment of the companies involved in the development of CAR T-cell therapies based on their year of establishment, company size and location of headquarters.

Examination of completed, ongoing, and planned clinical studies based on parameters, such as trial registration year, enrolled patient population, trial recruitment status, trial phase, target patient segment, type of sponsor / collaborator, most active players and regional distribution of trials.

An analysis of key insights derived from the study featuring a competitive analysis, emphasizing the prevalent target antigens associated with hematological malignancies and solid tumors. Additionally, it includes CAR construct analysis of clinical-stage CAR T cell therapies based on the generation of CAR (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of virus used (lentivirus and retrovirus), type of gene transfer method used (transduction and transfection) and type of co-stimulatory domain used.

An in-depth examination that emphasizes the key opinion leaders (KOLs) within this field includes an evaluation of various principal investigators overseeing clinical trials associated with CAR-T therapies. These investigators are recognized as KOLs due to their active engagement in the research and development of CAR T cell therapies. Additionally, the chapter provides a comparative analysis of the KOLs’ expertise, utilizing a proprietary scoring system alongside assessments from third-party evaluations.

In-depth profiles of key players in CAR T-cell therapy market, focusing on company overviews, and a brief description of the product portfolio specific to CAR-T therapies, technology portfolio (if available), recent developments related to CAR-T cell therapies and manufacturing capabilities of the companies. In addition, it also includes details of the strategic / venture capital investments made in these companies.

An analysis of partnerships established in this sector, covering R&D agreements, license agreements (specific to technology platforms and therapy candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements, joint ventures and others.

A detailed evaluation of the investments made in CAR T cell therapy companies with proprietary therapies and technologies, encompassing seed funding, venture capital, capital raised through IPOs and follow-on offerings, as well as grants and debt financing.

Detailed analysis of over 11,900 patents filed or granted related to CAR T-cell therapies based on type of patent, publication year, geographical distribution, Cooperative Patent Classification (CPC) symbols, emerging focus areas, type of applicant, leading players (on the basis of number of patents filed / granted), patent valuation and patent benchmarking.

A case study focused on the production of cell therapy products, emphasizing the challenges and providing a comprehensive list of contract service providers and in-house manufacturers involved in this domain.

A comprehensive evaluation of the various factors that underpin the pricing of cell-based therapies. It includes different models and strategies that a pharmaceutical company might consider when determining the price of a CAR-T cell therapy expected to be launched in the near future.

An analysis of the primary promotional strategies employed by the developers of approved CAR T cell therapies, including Tisagenlecleucel-T (KYMRIAH®), Axicabtagene ciloleucel (YESCARTA®), Brexucabtagene Autoleucel (TECARTUS™), Lisocabtagene maraleucel (Breyanzi®), Idecabtagene Vicleucel (Abecma™), and Ciltacabtagene Autoleucel (CARVYKTI™), among others.

KEY QUESTIONS ANSWERED IN THIS REPORT

How many companies are currently engaged in this market?

Which are the leading companies in this market?

What kind of partnership models are commonly adopted by industry stakeholders?

How many clinical trials are running for CAR-T therapies?

What are the factors that are likely to influence the evolution of this market?

What is the current and future market size?

What is the CAGR of this market?

How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.

Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.

The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

Complimentary PPT Insights Packs

Complimentary Excel Data Packs for all Analytical Modules in the Report

10% Free Content Customization

Detailed Report Walkthrough Session with Research Team

Free Updated report if the report is 6-12 months old or older